PERCEPTIVE ADVISORS LLC - 31 May 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role: Director, 10%+ Owner
Signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Issuer symbol: LYRA
Transactions as of: 31 May 2023
Transactions value $: $8,999,999
Form type: 4
Filing time: 02 Jun 2023, 16:11:06 UTC
Previous filing: 01 Jun 2023
Next filing: 06 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYRA	Common Stock	Purchase	$8,999,998	+3,610,832	+46%	$2.49	11,469,117	31 May 2023	See Footnotes	F1, F3, F4
holding	LYRA	Common Stock						1,288,446	31 May 2023	See Footnotes	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYRA	Common Stock Purchase Warrant	Purchase		+1,805,416			1,805,416	31 May 2023	Common Stock	1,805,416	$2.67	See Footnote	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund").
F2	The securities reported in this row are held by Perceptive LS (A), LLC ("Perceptive LS").
F3	Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS. Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F4	These securities were acquired in units, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock (the "Warrants"), at a combined purchase price of $2.4925 per unit. Each of the Warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer's outstanding shares of Common Stock following such exercise.